Monoclonal Antibodies Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 286.32 Bn

Forecast Year, 2035

USD 880.01 Bn

CAGR, 2026 - 2035

11.88%

Report Coverage

Global

What is the Monoclonal Antibodies Market Size?

The global monoclonal antibodies market size is calculated at USD 286.32 billion in 2025 and is predicted to increase from USD 321.83 billion in 2026 to approximately USD 880.01 billion by 2035, expanding at a CAGR of 11.88% from 2026 to 2035.

Market Highlights

• North America led the global market with the highest market share of 46.14% in 2025.
• By source, the human antibodies segment held the largest market share in 2025.
• By indication, the cancer segment captured the biggest revenue share in 2025.
• By distribution channel, the hospital pharmacies segment registered the maximum market share in 2025.

Market Overview

Monoclonal antibodies are witnessing a large increase in their use because of the rapidly growing number of people diagnosed with cancer, autoimmune disorders, and infectious disease. Monoclonal antibody therapeutic agents are generally much more specific and effective than other medications and have considerably less side effects. Research and development and expedited approval process in relation to biopharmaceuticals has and will continue to enhance the usage of monoclonal antibodies as a result of the ability to provide a targeted treatment approach. In addition, the rapidly increasing number of uses of monoclonal antibodies in diagnostics and immunotherapy will continue to support a continued growing market for monoclonal antibodies in the future.

Monoclonal Antibodies Market Growth Factors

The globe is witnessing a rapid spike in the new cases of cancer and various other chronic diseases among the population. As per the GLOBOCAN, a report by the International Agency for Research on Cancer (IARC), approximately 19.3 million new cancer cases and approximately 10 million cancer deaths across the globe were reported in 2020. This number (new cancer cases) is expected to rise by 47% from 2020 to 2040, globally. Therefore, it is estimated that around 28.4 million new cancer cases will be reported in 2040 across the globe. Thus, the surging prevalence of cancer and other chronic diseases is boosting the demand for biologics, which is expected to foster the growth of the global monoclonal antibodies market during the forecast period.

Furthermore, rising investment by the top pharmaceutical companies in the genomics research and development coupled with the emergence of technologically advanced genomic platforms like next-generation sequencing (NGS) is expected to significantly boost the market growth in the upcoming years. Moreover, the cost-effectiveness of the NGS platforms is boosting its adoption in the research and development of monoclonal antibodies. The mAbs are the widely accepted biologics that is expected to provide lucrative growth opportunities to the market players in the foreseeable future. The rising awareness among the patients and the healthcare service providers regarding the benefits and effectiveness of the monoclonal antibodies is expected to drive its demand.

Moreover, the approvals of several blockbuster monoclonal antibodies such as Remicade, Avastin, Rituxan, and Herceptin for the treatment of diseases like cancer, ulcerative colitis, rheumatoid arthritis, and Crohn's disease has significantly boosted the growth of the mAbs market across the globe.

Market Outlook

• Industry Growth Overview: As mentioned earlier, the monoclonal antibodies market, continues to grow due to increasing global disease burdens and the development of new therapeutic indications through continuous advancements within the field of monoclonal antibody technology as well as through consumer demand for new and innovative methods of targeting disease.
  
• Sustainability Trends: Sustainability will also drive continued growth for the monoclonal antibody market. More pharmaceutical companies are moving towards implementing sustainable manufacturing processes, such as reducing their environmental footprint while providing their customers with new, more sustainable options for packaging.
  
• Global Expansion: Global Expansion of the monoclonal antibodies market is taking place at an increasing rate as pharmaceutical companies are expanding internationally into Emerging Markets by forming licensing agreements and establishing local manufacturing partnerships.
  
• Startup Ecosystem: With regards to biotech companies, there has been an explosion of new start-ups entering the pipeline. Many of these start-ups are working to develop next-generation antibodies (bispecifics and antibody-drug conjugates).
  

MarketScope

Monoclonal Antibodies Market Segment Insights

[[segment_insights]]

Monoclonal Antibodies Market Regional Insights

[[regional_insights]]

Value Chain Analysis of Monoclonal Antibodies Market

[[value_chain]]

Monoclonal Antibodies Market Companies

• Johnson & Johnson
• Merck
• AbbVie
• Amgen
• GlaxoSmithKline plc.
• Norvatis AG
• Pfizer Inc.
• Thermofischer Scientific
• Elililly and Company
• Bristol-Myers Squibb

RecentDevelopments

• In October 2018, Amgen launched its biosimilar of adalimumab called Amgevita, in Europe
• In December 2019, CARsgen Therapeutics acquired IND (Investigational New Drug) clearance for its AB011 humanized mAb in China, for the treatment of pancreatic and gastric adenocarcinoma

Segments Covered in the Report

By Source

• Humanized mAb
• Human mAb
• Murine mAb
• Chimeric mAb

By Indication

• Cancer
• Breast cancer
• Colorectal cancer
• Lung cancer
• Ovarian cancer
• Others
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Production Methods

• In Vivo
• In Vitro

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa